Bioymifi is a potent and selective small molecule agonist of DR5, identified by a high-throughput chemical screening for compounds that promote cell death in synergy with a small-molecule mimetic of Smac. Bioymifi directly targets DR5, specifically binds the ECD of DR5 (Kd ~1.2 μM), and induces the formation of DR5 aggregates and DR5 activation. Bioymifi induces caspase-8–dependent apoptosis, which occurs through a DR5-dependent extrinsic pathway but independent of TRAIL. Bioymifi is capable of acting as a single agent to induce DR5 clustering and aggregation, leading to apoptosis without the need for a Smac mimetic in a variety of cancer cell lines, even in U2OS and HT29 cell lines. Bioymifi could be a potential lead compound for the development of small-molecule TRAIL mimics targeting DR5 for cancer therapy.
?
How to Use:
In vitro:??Bioymifi was used at 5-10 μM final concentration in vitro and in cellular assays.
In vivo:??n/a
?
Reference:
1. Wang G, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. (2012) Nat Chem Biol. 9(2):84-89.
? ?
? ?
Products are for research use only. Not for human use.